REFERENCES
  1. World Health Organization. Global Tuberculosis Report 2016. WHO/HTM/TB/2016.13. Geneva: World Health Organization 2016. Accessed 15 November 2019.
  2. World Health Organization. Global Tuberculosis Report 2018. WHO/CDS/TB/2018.20. Geneva: World Health Organization 2018. Accessed 18 November 2019.
  3. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010;51:6-14.
  4. Chang K, Lu W, Wang J, Zhang K, Jia S, Li F, et al. Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a meta-analysis. J Infection 2012;64(6):580-88.
  5. Dye C, Williams BG. Criteria for the control of drug-resistant tuberculosis. P Natl Acad Sci USA 2000;97(14):8180-85.
  6. World Health Organization. Rapid Implementation of the Xpert MTB/RIF Diagnostic Test 2011. http://whqlibdoc.who.int/publications/2011/9789241501569_eng.pdf. Accessed 30 November 2019
  7. Tortoli E, Russo C, Piersimoni C, Mazzola E, Dal MP, Pascarella M, et al. Clinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis. Eur Respir J 2012;40:442-47.
  8. Lawn SD, Mwaba P, Bates M, Piatek A, Alexander H, Marais BJ, et al. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis 2013;13(4):349-61.
  9. Sharma SK, Kohli M, Yadav RN, Chaubey J, Bhasin D, Sreenivas V, et al. Evaluating the diagnostic accuracy of xpert mtb/rif assay in pulmonary tuberculosis. PLoS One 2015; 10(10):e0141011.
  10. Christopher PM, Cucunawangsih, Widysanto A. GeneXpert Mycobacterium tuberculosis/rifampicin assay for molecular epidemiology of rifampicin-Resistant Mycobacterium tuberculosis in an Urban Setting of Banten province, Indonesia. Int J Mycobacteriol 2019;8(4):351-58.
  11. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid molecular detection of tuberculosis and rifampin resistance. New Eng J Med 2010;363:1005-15.
  12. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011;377(9776):1495-1505.
  13. International Union against Tuberculosis and Lung Disease. Sputum examination for tuberculosis by direct microscopy in low income countries. Technical Guide. 5th edition. Paris, France: IUATLD 2000.
  14. Chihota VN, Grant AD, Fielding K, Ndibongo B, van Zyl A, Muirhead D, et al. Churchyard GJ. Liquid vs. solid culture for tuberculosis: performance and cost in a resource-constrained setting. Int J Tuberc Lung D 2010;14(8):1024-31
  15. Feng JY, Huang SF, Ting WY, Chen YC, Lin YY, Huang RM, et al. Gender differences in treatment outcomes of tuberculosis patients in Taiwan: a prospective observational study. Clin Microbiol Infec 2012;18(9):E331-E337.
  16. Goel S, Siddiqi K, Singh RJ, Lal P, Aghi MB, Gupta P, et al. Fuelling the tuberculosis epidemic: The role of tobacco control in ending the TB emergency. IJTB 2019;66(4):555-60.
  17. Thomas BE, Thiruvengadam K, Rani S, Kadam D, Ovung S, Sivakumar S, et al. Smoking, alcohol use disorder and tuberculosis treatment outcomes: A dual co-morbidity burden that cannot be ignored. PLoS One 2019;14(7):e0220507.
  18. Ullah H, Ullah A, Khan MW. Assessment of factors affecting and causing Hepatitis B in Balochistan-Pakistan. PAB 2020;9(1):471-77.
Table 1. Characteristics of the TB suspects (N = 716), divided into groups according to diagnosis as TB positive or TB negative by GeneXpert method.